Nuvectis Pharma Future Growth
Future criteria checks 0/6
Nuvectis Pharma is forecast to grow earnings and revenue by 41.5% and 78.2% per annum respectively while EPS is expected to grow by 41.6% per annum.
Key information
41.5%
Earnings growth rate
41.6%
EPS growth rate
| Biotechs earnings growth | 27.5% |
| Revenue growth rate | 78.2% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 14 Nov 2024 |
Recent future growth updates
No updates
Recent updates
Nuvectis Pharma (NASDAQ:NVCT) Is In A Good Position To Deliver On Growth Plans
Oct 20
We Think Nuvectis Pharma (NASDAQ:NVCT) Needs To Drive Business Growth Carefully
Jun 26Is Nuvectis Pharma (NASDAQ:NVCT) In A Good Position To Deliver On Growth Plans?
Jan 06Here's Why We're Not Too Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Situation
Oct 03We're Not Very Worried About Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Rate
Jan 31Nuvectis Pharma forms scientific advisory board for research and development of drugs
Sep 28Nuvectis Pharma GAAP EPS of -$0.28 misses by $0.04
Aug 05Nuvectis Pharma declines 13%, announces $15.9M private placement
Jul 27We're Keeping An Eye On Nuvectis Pharma's (NASDAQ:NVCT) Cash Burn Rate
May 04Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 2 | -23 | N/A | N/A | 3 |
| 12/31/2025 | N/A | -20 | N/A | N/A | 3 |
| 12/31/2024 | N/A | -18 | N/A | N/A | 3 |
| 9/30/2024 | N/A | -19 | -14 | -14 | N/A |
| 6/30/2024 | N/A | -21 | -14 | -14 | N/A |
| 3/31/2024 | N/A | -22 | -16 | -16 | N/A |
| 12/31/2023 | N/A | -22 | -16 | -16 | N/A |
| 9/30/2023 | N/A | -22 | -16 | -16 | N/A |
| 6/30/2023 | N/A | -22 | -17 | -17 | N/A |
| 3/31/2023 | N/A | -20 | -15 | -15 | N/A |
| 12/31/2022 | N/A | -19 | -14 | -14 | N/A |
| 9/30/2022 | N/A | -15 | -11 | -11 | N/A |
| 6/30/2022 | N/A | -13 | -11 | -11 | N/A |
| 3/31/2022 | N/A | -16 | -13 | -13 | N/A |
| 12/31/2021 | N/A | -13 | -10 | -10 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: NVCT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: NVCT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: NVCT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: NVCT is forecast to have no revenue next year.
High Growth Revenue: NVCT is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if NVCT's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/20 13:50 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Nuvectis Pharma, Inc. is covered by 3 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joseph Pantginis | H.C. Wainwright & Co. |
| Aydin Huseynov | Ladenburg Thalmann & Company |
| Jonathan Aschoff | Roth MKM |